Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms

MLA

Chatzellis, E.Angelousi, A.Daskalakis, K.Tsoli, M.Alexandraki, K. I.Wachuła, E.Meirovitz, A.Maimon, O.Grozinsky-Glasberg, S.Gross, D.Kos-Kudła, B.Koumarianou, A.Kaltsas, G. Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms. Jan. 2019. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.od......2127..e8526e72a4713949b563489e028411c1&authtype=sso&custid=ns315887.

APA

Chatzellis, E. A. A. D. K. T. M. A. K. I. W. E. M. A. M. O. G.-G. S. G. D. K.-K. B. K. A. K. G. (2019). Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms.

Chicago

Chatzellis, E. Angelousi, A. Daskalakis, K. Tsoli, M. Alexandraki, K.I. Wachuła, E. Meirovitz, A. Maimon, O. Grozinsky-Glasberg, S. Gross, D. Kos-Kudła, B. Koumarianou, A. Kaltsas, G. 2019. “Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.od......2127..e8526e72a4713949b563489e028411c1&authtype=sso&custid=ns315887.